Evaxion A/SEVAX

Evaxion Biotech’s latest stunt is to wheel three-year efficacy data for its AI-designed cancer vaccine EVX-01 onto the stage at the ESMO Congress 2026 in under a fortnight, a manoeuvre that turns a clinical-stage company into a conference-stage one. The headline sounds like a breakthrough, but the only measurable supplied is the date: 17 July 2026. The product’s ‘three-year clinical efficacy data’ are presented in an abstract, not in a peer-reviewed journal, and the company’s own investor rail offers no revenue, profit, or cash figure to anchor the claim. What is certain is that the slide deck will be polished, the soundtrack will be upbeat, and the balance sheet will remain comfortably out of frame. (source: Jul 17, 2026 Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026, https://evaxion.ai/?press_release_id=11251)

Evaxion’s marketing machinery is currently running on a loop of ‘new preclinical data’ for its cytomegalovirus vaccine candidate EVX-V1, which the company has presented twice this month: once at the International Herpesvirus Workshop on 1 July and again on 12 July. The word ‘new’ is doing heavy lifting here; the data are described only as ‘further supporting the multi-component concept,’ a phrase that tells the market nothing about durability, safety, or timelines. The company’s pipeline page and investor centre are awash with the same boilerplate about a ‘proprietary, clinically validated and scalable AI platform, AI-Immunology™,’ yet the evidence file contains no clinical-trial registration identifiers, no regulatory correspondence, and no financial metrics. The gap between the polished platform story and the plain operating reality is now a slide deck’s width. (sources: Jul 1, 2026 Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop, https://evaxion.ai/?press_release_id=11226; Jul 12, 2026 Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1, https://evaxion.ai/?press_release_id=11241)

Evaxion’s cash runway is the one metric the company does not publish. The investor rail lists press releases, upcoming events, and shareholder updates, but not cash, burn, or capitalisation. The product evidence is limited to posters, abstracts, and conference slots-useful for brand visibility, useless for valuation. The company’s own website still carries the tagline ‘pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™,’ yet the only clinical validation Evaxion has supplied to the public is a pair of preclinical posters. The risk is that the AI platform’s output exceeds the company’s ability to fund the next step, and the only certainty is that the next press release will arrive before any audited accounts. (sources: Press releases | Evaxion, http://evaxion.ai/investors/press-releases/; Press releases | Evaxion, https://evaxion.ai/investors/press-releases/)

Evidence aside, the company’s share-price chart is a blank canvas because the rail supplies no price data, volume, or venue. The company trades on the Nasdaq Copenhagen under the ticker EVAX, but the evidence file contains no liquidity metrics, no bid-ask spread, and no trading volumes. The sensible reader must treat the price route as a placeholder; the real plumbing is missing. If you need a chart, the route is https://www.tradingview.com/symbols/OM-EVAX/ on the OMX Copenhagen exchange, but the chart will show only the absence of data rather than any actionable level. (source: OMX Copenhagen EVAX symbol route, https://www.tradingview.com/symbols/OM-EVAX/)